Alemtuzumab treatment can affect CD52 positive as well as CD52 negative GPI-deficient, Sezary

Author(s):
Vermeer, M.H.; Fits, L. van der; Jedema, J.; Egmond, H.M. van; Falkenburg, J.H.F.; Halkes, C.J.M.
Published
2011
Publication type
Article / Letter to editor
Date issued
2011-10-31
Language
English
Is part of
JDDG (2011), Vol. 9, p. 1-1
hdl
1887/118367